Vinorelbin
Generic Name
vinorelbin-30-mg-capsule
Manufacturer
Various Pharmaceutical Manufacturers
Country
Global
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vinorelbin 30 mg capsule | ৳ 5,750.00 | N/A |
Description
Overview of the medicine
Vinorelbine is an anticancer drug belonging to the vinca alkaloid class. It is used in the treatment of various cancers, primarily non-small cell lung cancer and metastatic breast cancer.
Uses & Indications
Dosage
Adults
Typically, 60 mg/m² orally once a week for the first 3 weeks, then increased to 80 mg/m² once a week if tolerated, as part of a multi-week cycle. Dose adjustments are made based on hematologic parameters.
Elderly
Similar to adults, but with careful monitoring due to potential reduced hepatic or renal function.
Renal_impairment
No specific dose adjustment recommended, but use with caution in severe impairment.
How to Take
Take the capsule whole with water. Do not chew or suck the capsule. It can be taken with or without food. If vomiting occurs shortly after taking, do not repeat the dose; consult physician.
Mechanism of Action
Vinorelbine selectively inhibits microtubule polymerization by binding to tubulin, leading to mitotic arrest at metaphase and inducing apoptosis in cancer cells.
Pharmacokinetics
Onset
Not immediately discernible, action related to cell cycle disruption over time.
Excretion
Mainly eliminated via biliary/fecal route; a small portion is excreted renally.
Half life
Terminal half-life ranges from 25 to 40 hours.
Absorption
Rapidly absorbed after oral administration. Absolute bioavailability is approximately 40%.
Metabolism
Extensively metabolized in the liver, primarily by CYP3A4 enzyme.
Side Effects
Contraindications
- Hypersensitivity to vinorelbine or other vinca alkaloids
- Severe neutropenia (absolute neutrophil count <1500 cells/mm³)
- Severe hepatic impairment unrelated to the malignancy
- Current severe infection
Drug Interactions
Live Vaccines
Risk of severe, potentially fatal, infection.
Other Myelosuppressive Agents
Increased risk of severe myelosuppression.
CYP3A4 Inducers (e.g., phenytoin, rifampicin)
May decrease vinorelbine plasma concentrations, reducing efficacy.
CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin)
May increase vinorelbine plasma concentrations, increasing toxicity.
Storage
Store at room temperature (15-30°C), away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include severe myelosuppression with fever and infections, severe gastrointestinal toxicity, and severe neurotoxicity. Management is supportive, including colony-stimulating factors for neutropenia and close monitoring of vital signs.
Pregnancy & Lactation
Vinorelbine is contraindicated during pregnancy due to potential fetal harm (Category D). It is not known if vinorelbine is excreted in human milk, but due to potential serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment.
Side Effects
Contraindications
- Hypersensitivity to vinorelbine or other vinca alkaloids
- Severe neutropenia (absolute neutrophil count <1500 cells/mm³)
- Severe hepatic impairment unrelated to the malignancy
- Current severe infection
Drug Interactions
Live Vaccines
Risk of severe, potentially fatal, infection.
Other Myelosuppressive Agents
Increased risk of severe myelosuppression.
CYP3A4 Inducers (e.g., phenytoin, rifampicin)
May decrease vinorelbine plasma concentrations, reducing efficacy.
CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin)
May increase vinorelbine plasma concentrations, increasing toxicity.
Storage
Store at room temperature (15-30°C), away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include severe myelosuppression with fever and infections, severe gastrointestinal toxicity, and severe neurotoxicity. Management is supportive, including colony-stimulating factors for neutropenia and close monitoring of vital signs.
Pregnancy & Lactation
Vinorelbine is contraindicated during pregnancy due to potential fetal harm (Category D). It is not known if vinorelbine is excreted in human milk, but due to potential serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
FDA/DGDA Approved
Patent Status
Off-patent
Clinical Trials
Ongoing clinical trials are exploring vinorelbine in combination with other agents for various solid tumors and its use in different dosing schedules.
Lab Monitoring
- Complete Blood Count (CBC) with differential, weekly or before each dose
- Liver Function Tests (LFTs)
- Renal Function Tests (RFTs)
- Serum electrolytes
Doctor Notes
- Emphasize the critical importance of weekly CBC monitoring prior to each dose to manage myelosuppression.
- Educate patients about signs of infection and advise prompt reporting of fever.
- Counsel on appropriate management of gastrointestinal side effects and peripheral neuropathy.
Patient Guidelines
- Report any signs of fever, infection, or unusual bleeding/bruising immediately.
- Maintain good hygiene to reduce infection risk.
- Adhere strictly to the prescribed dosage and schedule.
- Avoid contact with people who have infections.
Missed Dose Advice
If a dose is missed, contact your doctor immediately. Do not take a double dose to make up for a forgotten one.
Driving Precautions
Vinorelbine may cause fatigue, dizziness, or visual disturbances. Patients should be advised to exercise caution when driving or operating machinery.
Lifestyle Advice
- Avoid grapefruit and grapefruit juice during treatment.
- Stay well-hydrated by drinking plenty of fluids.
- Manage fatigue by getting adequate rest and light exercise if tolerated.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.